oncgnostics at Medica 2022: Cervical cancer screening test conquers China Establishing early detection of head and neck tumours First study results for screening test for vulva and vaginal cancer At the joint stand of medways e.V. in Hall 15, Stand K10 Jena / Düsseldorf, November 08, 2022 – oncgnostics GmbH will present its technology, products […]
The company oncgnostics GmbH, founded in 2012, already launched its first product in 2015: the diagnostic test for cervical cancer “GynTect”. This is now sold in over ten countries in Europe and Asia. In addition, oncgnostics conducts research in the field of diagnostics for head and neck cancer. The company is growing steadily and has […]
Dr. Carolin Dippmann and Daria Meyer from our research and development team work, among other things, with the “third-generation sequencing” method. With the help of this technology, they are examining DNA (deoxyribonucleic acid) from tumors much more precisely than was previously possible. The method has enormous advantages: epigenetic changes in the DNA, specifically DNA methylation […]
We look back on the milestones of 2021 – and forward to upcoming projects. In May, we moved the entire company within Jena, thus gaining space for more office workspace and a better layout of the labs. Recently, our team grew by one colleague, so that we are now 18 people. One of the reasons […]
Every year, about 7,300 women in Germany are diagnosed with ovarian cancer (ovarian carcinoma), and more than 5,000 die of the consequences. This means that one in 72 women will be diagnosed with ovarian cancer at some point in their lives. In those affected, cells on one or both ovaries change malignantly and begin to […]
As a biotechnology company, we have been researching cancer diagnostics on a molecular basis since 2012. We deal with epigenetic markers, which help us to recognise cancers, such as cervical cancer, in their preliminary stages. In this article, we explain the terms “epigenetics” and “epigenetic marker”. Epigenetics – what is it? Epigenetics deals with the […]
A large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much less frequent since the onset of the corona pandemic. A study by Hannover Medical School and the biotechnology company oncgnostics GmbH is testing self-tests as […]
What has to be considered if you want to start as a German biotech company on the American market? What are the legal bases and challenges there? We got an insight at the “Step USA Virtual” from June 28th until July 1st, 2021. The four-day startup boot camp took place in New York and, due […]
Since the beginning of 2020, when early cervical cancer screening in Germany was supplemented by a routine HPV test for women over 35, more people have been confronted with a positive test result. First, it is important to mention: This is not a reason to panic. A positive HPV test result is not to be […]
At the beginning of May, things were turbulent, because we moved into our new offices and laboratories. The new location in a business park in Jena enables us to create more opportunities for our company growth and to increase our (international) sales. It was the first time we’ve moved since the company was founded in […]